Thank you for attending CHC!
Clinicial Presentations
Click on the presentation title to access clinical slide decks
Plasma Cell Dyscrasias
New Developments in Amyloidosis
Dr. Chris Venner – Cross Cancer Institute
Myeloma 2020 and Beyond
Dr. Keith Stewart – Princess Margaret Cancer Centre
Treatment of Relapsed Refractory Multiple Myeloma in the Canadian Landscape
Dr. Kevin Song – BC Cancer
Chronic Lymphocytic Leukemia
Where Are We Headed in CLL?
Dr. Michael Hallek – Universität zu Köln (Cologne, Germany)
Front Line Management of CLL
Dr. Graeme Fraser – Juravinski Cancer Centre
Relapse CLL in 2020
Dr. Carolyn Owen – University of Calgary
Immunotherapy
The Challenges Ahead: A Translational Science Perspective on Immunotherapy
Rob Laister, Translational Scientist, PhD – Princess Margaret Cancer Centre
Cell Therapy
Dr. Ronan Foley – Juravinski Cancer Centre
Antibody-Based Immunotherapy
Dr. John Kuruvilla – Princess Margaret Cancer Centre
Non-Hodgkin Lymphoma I
Axicabtagene Ciloleucel in DLBCL: Determinants of Efficacy
Dr. Frederick Locke – Moffitt Cancer Center (Florida, USA)
Relapsed Follicular Lymphoma: A Therapeutic Challenge
Dr. Michael Crump – Princess Margaret Cancer Centre
The Use of RT in NHL in Canada: Evolving Paradigms
Dr. Richard Tsang – Princess Margaret Cancer Centre
Acute Leukemia, MDS, & MPNs
AML in 2020: Evolving Therapeutics that are Changing Therapy
Dr. Eunice Wang – Roswell Park Comprehensive Cancer Center (New York, USA)
New Developments in MDS Diagnosis, Prognosis, and Therapy
Dr. Rena Buckstein – Odette Cancer Centre
Reviewing MPNs in 2020: A Practical and Therapeutic Approach
Dr. Vikas Gupta – Princess Margaret Cancer Centre
Translational Science
Towards Biology – Informed Management of B-Cell Lymphoma
Dr. Robert Kridel – Princess Margaret Cancer Centre
Immunoprofiling for the Clinician: Lessons from Cell Therapy
Dr. Marcus Butler – Princess Margaret Cancer Centre
Non-Hodgkin Lymphoma II
Mantle Cell Lymphoma: Current Standards and Future Perspectives
Dr. Martin Dreyling – LMU Hospital (Munich, Germany)
Current Management Approaches to Patients with Non-MALT Marginal Zone Lymphoma
Dre Catherine Thieblemont – Hôpital Saint-Louis (Paris, France)
Treatment Landscape of Waldenström Macroglobulinemia
Dr. Steve Treon – Dana-Farber Cancer Institute (Massachusetts, USA)
Marginal Zone Lymphoma
Dr. Emanuele Zucca – Oncology Institute of Southern Switzerland (Bellinzona, Switzerland)
PET-Pearls and PET-Falls: The Role in Follicular Lymphoma
Dr. Judith Trotman – Concord Repatriation General Hospital (Sydney, Australia)
Hodgkin Lymphoma
Limited Stage Hodgkin’s Lymphoma in 2020: A Practical Approach Based on Today’s Data
Dr. Martin Hutchings – Rigshospitalet (Copenhagen, Denmark)
Advanced Hodgkin’s Lymphoma in 2020: A Practical Approach Based on Today’s Data
Dr. Jonathan Friedberg – Wilmot Cancer Institute (New York, USA)
How we treat R/R-cHL in Canada in 2020
Dr. John Kuruvilla – Princess Margaret Cancer Centre
Radiation Therapy in Hodgkin Lymphoma 2020: Balancing Risks
Dr. David Hodgson – Princess Margaret Cancer Centre
About CHC 2020
CHC is the largest multi-disciplinary hematological conference across Canada. It brings together a pan-Canadian and International Faculty to showcase cutting-edge research and developments in the field of hematology. This meeting covers a breadth of topics, including (but not limited to): Plasma Cell Dyscrasias, Non-Hodgkin’s Lymphoma, Hodgkin’s Disease, Chronic Lymphocytic Leukemia, Immunotherapy, Translational Science, Leukemia & MDs.
Dr. John Kuruvilla (Princess Margaret Cancer Centre) and Dr. Peter Anglin (Stronach Regional Cancer Centre) will co-chair this event. CHC 2020 is open to Canadian hematology professionals, including residents, nurses, pharmacists, and specialists who have an interest in hematology.
Thank You to our Sponsors!
